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Abstract
Pulmonary hypertension (PH) is highly heterogeneous and despite treatment advances it remains a life-shortening condition. There
have been significant advances in imaging technologies, but despite evidence of their potential clinical utility, practice remains
variable, dependent in part on imaging availability and expertise. This statement summarizes current and emerging imaging
modalities and their potential role in the diagnosis and assessment of suspected PH. It also includes a review of commonly
encountered clinical and radiological scenarios, and imaging and modeling-based biomarkers. An expert panel was formed including
clinicians, radiologists, imaging scientists, and computational modelers. Section editors generated a series of summary statements
based on a review of the literature and professional experience and, following consensus review, a diagnostic algorithm and 55
statements were agreed. The diagnostic algorithm and summary statements emphasize the key role and added value of imaging in
the diagnosis and assessment of PH and highlight areas requiring further research.
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Introduction
Pulmonary hypertension (PH) is highly heterogeneous, is
challenging to diagnose and treat, and has a survival
worse than many forms of common cancer.1,2 It ranges
Corresponding author:
David G. Kiely, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS
Foundation Trust, Sheffield, S10 2JF, UK.
Email: david.kiely@sth.nhs.uk
Creative Commons CC-BY: This article is distributed under the terms of the Creative Commons Attribution 4.0
License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution
of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access
pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).




from a rare form, pulmonary arterial hypertension (PAH),
characterized by a vasculopathy and frequently severe ele-
vation of pressure, to more common usually mild elevations
of pulmonary artery pressure (PAP) seen in severe cardiac
and respiratory disease.3,4 The current system of classifica-
tion identifies five groups, each with distinct pathophysio-
logical characteristics.2,3,5 The diagnosis of PH is usually
first suggested by echocardiography or chest radiography
with confirmation of an elevated PAP at right heart cath-
eterization (RHC). Phenotyping is based on a careful his-
tory, blood testing for associated conditions, detailed
physiological, and imaging investigations.
The treatment of PH is dependent on the underlying cause.
For patients with PAH, drug therapy targeting imbalances in
vasoconstrictor and vasodilator mediators have been shown
to improve exercise capacity, quality of life, and event-free
survival.6–13 However, PAH remains a life-limiting and debil-
itating condition. In chronic thromboembolic pulmonary
hypertension (CTEPH), pulmonary endarterectomy is an
established technique with excellent long-term outcomes14–18
and, more recently, drug therapy19–21 and balloon pulmonary
angioplasty (BPA)22,23 have shown benefit in selected groups
of patients with CTEPH. For patients with other forms of
PH, such as in association with cardiac and respiratory dis-
ease, trials of PAH therapies have thus far been disappoint-
ing.24–26 Accurate classification is key, not only as it defines
treatment but also prognosis27–29 and careful assessment
is therefore crucial in the assessment of patients with sus-
pected PH.
Current assessment tools in the PH clinic and endpoints
used in clinical trials may be limited by a number of factors.
These include insensitivity to change, lack of repeatability,
and the invasive nature of tests. There is a need to identify
new tools and endpoints to aid the physician both in the
clinical environment and in studies of new interven-
tions.30–36 Importantly, over the last 20 years, there has
been major advances in imaging techniques and their appli-
cation including the use of echocardiography, nuclear medi-
cine, computed tomography (CT) scanning, magnetic
resonance imaging (MRI), and molecular imaging.
There is growing evidence demonstrating the value of vari-
ous imaging modalities in the classification, risk stratifica-
tion, and follow-up of patients with PH. Imaging studies
have also provided insights into pathophysiological
mechanisms.37–45
The use of imaging varies across the globe due to a var-
iety of factors including personal preference, availability,
and cost. Given the complex nature of certain imaging inves-
tigations, there are also differences in methods of scan acqui-
sition and post-processing within a given modality.
Consequently, the Pulmonary Vascular Research Institute
(PVRI) have identified imaging as an important area for
international collaboration, with the aim of developing evi-
dence-based statements and sharing best practice, while
recognizing that approaches need to be tailored to imaging
availability. This statement on imaging in PH is aimed at
physicians (including cardiologists and pulmonologists), PH
specialists, radiologists, and imaging scientists.
Methods
The PVRI Imaging Task force met for the first time in Rome
in 2016 with an aim of improving imaging practice globally
in PH. A summary statement from the PVRI was identified
as an important first step in achieving this goal. Participants
were invited from the existing PVRI membership in addition
to international imaging experts. The group included repre-
sentatives from wide-ranging professional backgrounds and
different geographical areas with varied access to imaging.
Groups of authors were assigned to specific sections to
review current literature, identify summary statements, and
develop a diagnostic algorithm. An editorial board met to
preview and refine summary statements and ensure uniform-
ity of style (DGK, DL, JVC, and AJS). To be included in
the final document, summary statements required agreement
of 80% of authors. Statements not meeting this requirement
were reworded until this threshold was reached or the state-
ment rejected. Given the rapid development of imaging tech-
nologies, the recommendations reflect a combination of
published evidence, current practice, and expert opinion.
All authors read and approved the manuscript before
submission.




1. A chest radiograph is recommended as the initial imaging
test in the assessment of unexplained breathlessness.
2. A normal chest radiograph does not exclude the diagno-
sis of PH
3. Features of PH include pulmonary artery (PA) enlarge-
ment and cardiomegaly.
Chest radiography. Patients with PH frequently present with
breathlessness. The principal role of the chest radiograph
(CXR) is to identify other common causes of breathlessness
(e.g. parenchymal lung disease, pneumonia, pulmonary
edema, pleural effusion, and pneumothorax). The findings
of PH on CXR vary. There may be enlargement of the cen-
tral pulmonary arteries with pruning of the peripheral ves-
sels, features that were observed in the majority of patients
in a registry of patients with idiopathic PAH.46 In addition,
cardiomegaly and features suggestive of right atrial enlarge-
ment may be observed. However, a normal CXR cannot
exclude the diagnosis and the CXR may be normal, where
PAP elevation is modest. Radiographic features may also
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suggest the cause of PH, such as upper lobe venous diver-
sion and left atrial enlargement in patients with left heart
disease, vascular plethora, and peripheral pruning in
patients with Eisenmenger physiology, and interstitial opa-
cities in patients with diffuse parenchymal lung disease.
1.2: Echocardiography
Summary statements
1. Echocardiography is the test of choice in the initial evalu-
ation of suspected PH.
2. Echocardiography should include an assessment of PAP,
cardiac, and valvular function.
3. A probability of PH should be generated using estimated
PAP and additional echocardiographic features.
Doppler and two-dimensional (2D) echocardiography
remains the screening test of choice in the evaluation of sus-
pected PH.47–50 While right ventricular systolic pressure
(RVSP) from the continuous wave Doppler of the peak tri-
cuspid regurgitant velocity (TRV) is the most well-known
tool for assessing the presence or absence of PH, this metric
can be subject to several limitations resulting in over or under
estimation of the true pulmonary artery systolic pressure
(PASP).51 Over the last decade, there have been many studies
evaluating the role of clinically useful and readily available
echo-Doppler parameters that allow one to move beyond the
PASP and assess not just the likelihood of PH, but also the
hemodynamic underpinnings of the disease (i.e. left heart dis-
ease vs. PAH).52,53 As noted in the most recent European
Society of Cardiology (ESC)/European Respiratory Society
(ERS) PH guidelines, ‘‘echocardiography should always be
performed when pulmonary hypertension is suspected and
may be used to infer a diagnosis of pulmonary hypertension
in patients in whom multiple different echocardiographic
measurements are consistent with this diagnosis,’’ even in
the absence of an elevated TRV.54 This can then be used to
generate a probability of PH which will inform the diagnostic
strategy and ‘‘decide the need for cardiac catheterization in
individual patients.’’54 Furthermore, several echo-Doppler
parameters have been shown to have prognostic value in
the setting of established PH.
Clinically useful measures of PH (i.e. elevated RV after-
load) on echocardiography include characteristics of the RV
outflow tract (RVOT) pulse wave Doppler envelope such as
a reduced acceleration time (<100ms),53,55–57 systolic notch-
ing,53,58,59 and pulmonary insufficiency velocity to estimate
mean PAPs (mPAP), as well as interventricular septal flat-
tening (as characterized by the eccentricity index),60
increased right-to-left ventricular ratio (0.8–1.0, 1.1–1.4,
and 1.5 corresponding to mild, moderate, and severe RV
dilatation, respectively),52,54 RV hypertrophy and right
atrial dilation61 and measures of RV function including tri-
cuspid annular plane systolic excursion (TAPSE),62,63 and
RV fractional area change (RVFAC).63–65 While RVFAC is
often limited in the setting of severe RV enlargement,52,63,66
TAPSE is a reproducible measure of RV function which
measures the total displacement of the heart from the RV
base toward the apex in systole, and correlates with radio-
nuclide-derived RV ejection fraction (RVEF).63 TAPSE has
also been shown to be prognostic of poor outcome in PH in
all-comers,62 as well as in follow-up assessment in a PAH
population after initiation of PH therapy.67,68 However,
TAPSE has not been shown as an effective marker of RV
function in pediatric PH.69 Other echocardiographic meas-
ures include the myocardial performance (Tei) index70 and
S’ obtained from tissue Doppler imaging of the tricuspid
annulus.71 Markers of adverse outcomes include pericardial
effusion and enlarged right atrium.72 More recently, RV
longitudinal strain using 2D speckle tracking has been
employed in the quantification of RV function in patients
with PH and has been shown to be impaired in patients with
PH, a predictor of mortality73–76 and useful for assessment
of therapy response.77,78 Lastly, given the complex anatomy
of the right ventricle, recent investigation has focused on the
use of three-dimensional (3D) echocardiography79 and
strain to assess global and regional RV structure and func-
tion and predict outcomes in PH.80
1.3 Nuclear medicine imaging
Summary statements
1. A normal perfusion single photon emission computed
tomography (SPECT) excludes chronic thromboembolic
disease that will benefit from pulmonary endarterectomy
and BPA.
2. Ventilation and perfusion SPECT or SPECT CT is super-
ior to planar scintigraphy.
3. In unexplained hypoxemia, a nuclear medicine shunt
assessment can be used to identify the presence of a
right-to-left shunt.
4. In patients with suspected PA sarcoma, positron-emis-
sion tomography (PET) is recommended.
Ventilation/perfusion (V/Q) SPECT is recommended by the
ESC as the first line screening test for patients with
CTEPH.1 The technique is well established and has excellent
diagnostic value particularly in the absence of lung disease.
The perfusion image involves exposure to ionizing radiation
and requires injection of 99mTc labelled macroaggregated
human albumin (10–90mm in diameter).20 The macro-aggre-
gated albumin becomes trapped within the small pulmonary
arterioles and a 3D image of pulmonary perfusion is acquired.
In CTEPH, typically peripheral wedge-shaped defects of vary-
ing size are shown. Mismatch to ventilation can be confirmed
by comparing ventilation and perfusion images. The added
value of performing ventilation imaging is debated and in
many centers perfusion imaging alone is performed and com-
pared to CT which better demonstrates parenchymal lung dis-
ease. CTEPH may be missed on CT as attenuated distal
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vessels, subsegmental stenosis, and webs may not be appre-
ciated. Early studies demonstrated that scintigraphy was
more sensitive than CT for the detection of CTEPH.
However, given advances in technology, more recent studies
have shown that CT pulmonary angiography and CT SPECT
techniques are equally sensitive.21–23 Dual-energy CT (DECT)
or CT with iodine mapping allow construction of relative per-
fusion maps in addition to providing angiographic images.81–87
Given that 99mTc labelled macroaggregates are trapped by
small pulmonary arterioles, the presence of radioactive
uptake in organs supplied by the systemic circulation (e.g.
the kidneys) can be used to identify the presence of a right-
to-left shunt in hypoxemic patients with PH.19
Positron-emission tomography (PET) allows for observa-
tion of metabolic activity in the body which can be recon-
structed to produce 3D images. Fluorodeoxyglucose (FDG),
a glucose analogue, can be used to assess glucose uptake in
tissues. PET scanning is commonly performed with simul-
taneous acquisition of CT and more recently with MRI for
both functional and structural correlation.28 In patients with
suspected PA sarcoma, PET will show high uptake allowing
differentiation from chronic clot.29,30 However, in acute clot
FDG, uptake may also be elevated, relative to unaffected
vessels.88 In PAH, uptake within the lungs and right ven-




1. CT provides a non-invasive evaluation of vascular, car-
diac, lung parenchymal, and mediastinal structures in
patients with known or suspected PH.
2. Significant parenchymal abnormalities may be seen on
CT evaluation in the presence of normal spirometry, par-
ticularly when there is a significant reduction in gas trans-
fer factor.
3. CT pulmonary angiography to assess the pulmonary
vasculature should be considered in patients presenting
with PH.
4. Imaging biomarkers from CT in patients with suspected
PH should include measurement of PA size, right-to-left
ventricular ratio, and left atrial size.
5. CT aids the classification of PH.
CT is increasingly recognized as a valuable imaging modal-
ity for the evaluation of known or suspected PH.
Advantages of CT include its widespread availability and
accessibility, high spatial resolution, multi-planar imaging
capabilities, and the ability to evaluate the pulmonary vas-
culature, lung parenchyma, cardiac, and mediastinal struc-
tures simultaneously.
CT evaluation of vessels. PA size can be easily measured and
enlargement may suggest the diagnosis of PH. Routine
measurement is recommended particularly in patients at
risk of PH. For the diagnosis of PH in lung disease, a
main PA diameter >29mm had 84% sensitivity, 75% spe-
cificity, and 97% positive predictive value (PPV) for PH
defined as a mPAP 25mmHg.89 The reliability of measur-
ing the main PA diameter and the ratio of the PA to aorta
(Ao) ratio has also been studied in suspected PH.
Investigators found that a PA:Ao ratio> 1 was 92% specific
for a mPAP> 20mmHg.90 Other reports also support the
use of PA size in the clinical assessment of patients with
PH.91,92 However, it has been shown that an increase in
PA size also reflects disease duration and correlates only
moderately with PAP.93 It has previously been postulated
that the presence of interstitial lung disease independently
influences PA size;94 however, in a large cohort of patients
with suspected PH in association with interstitial lung dis-
ease, the presence and severity of interstitial lung disease did
not influence PA size which was found to be a useful diag-
nostic marker in patients with and without interstitial lung
disease.95
While contrast-enhanced CT angiography is the method
of choice for the evaluation of suspected acute pulmonary
embolism, its role in the evaluation of the pulmonary vas-
culature in the setting of CTEPH has been a more recent
development. Multiple findings are associated with CTEPH,
including intravascular organizing thrombi, webs, and
regions of vascular narrowing or occlusion.96 Mosaic perfu-
sion of the lung parenchyma and enlarged bronchial arteries
are also commonly seen.97–99
Advanced CT capabilities have been studied in the evalu-
ation of PH. DECT provides an assessment of relative per-
fusion and improves the detection of peripheral vascular
occlusion. In one study,85 DECT showed 100% sensitivity
on a per-patient basis compared to V/Q scintigraphy.
However, there was imperfect agreement on a per-vessel
basis. CT perfusion imaging may demonstrate residual per-
fusion abnormalities following therapy for acute pulmonary
embolism, even in the absence of visualized thrombus on the
angiographic portions of the study.100 Perfusion imaging
can also estimate cardiac output and in a small pilot study
could detect PH with high sensitivity and specificity.101,102
PAH is associated with vascular remodeling, including
loss of arterial branching and increased vessel tortuosity.
CT angiography can quantify these features, using fractal
dimension and the ratio of actual vessel length to shortest
linear distance to estimate tortuosity. Studies have shown
these to correlate with hemodynamic measures in PAH.103
However, changes in the fractal dimension were found only
in children with PAH, but not in adults.104 Loss of distal
vascular volume has also been described in patients with
severe emphysema105 and in patients with CTEPH.106
CT evaluation of lung parenchyma. CT is the gold standard for
the evaluation of the lung parenchyma. In a large registry
series, CT measures have proven useful clinically in
the assessment of patients with PAH.38 Centrilobular
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ground-glass opacities are frequently seen in PAH and their
presence on a CT performed for unexplained breathlessness
should raise the possibility of this diagnosis.38,107,108
Features of cardiac decompensation, pleural effusion/
septal lines, and inferior vena cava size predict outcome.38
The presence of emphysema or interstitial lung disease or
bronchiectasis makes the diagnosis of PH in association
with lung disease likely. The addition of expiratory imaging
is helpful to assess for small airways disease. CT may also
identify features associated with rare conditions such as pul-
monary veno-occlusive disease (PVOD) and pulmonary
capillary hemangiomatosis (PCH) (section 2.2). This is an
important differential diagnosis to idiopathic PAH (IPAH)
because PAH therapy may be indicated but has a much
higher risk of severe adverse effects than IPAH.
CT evaluation of cardiac structure and function. CT has historic-
ally not been used for the evaluation of cardiac structural
abnormalities as MRI and echocardiography are the current
modalities of choice. Nonetheless, many cardiac findings
associated with PH can be identified with non-gated con-
trast-enhanced CT, including enlargement of cardiac cham-
bers, thickening of the RV free wall, and leftward deviation
of the interventricular septum. CT can also identify struc-
tural abnormalities associated with congenital heart disease,
such as partial anomalous pulmonary venous return and
intracardiac shunts. Electrocardiogram-gated CT can be
used to quantitatively assess RV and left ventricular (LV)
function. Additionally, a decrease in distensibility of the
main PA is highly correlated with the presence of
PAH.109–111 A study has shown that dynamic contrast-
enhanced CT can measure the transit of contrast, correlated
with cardiac output.102 and is associated with the presence
of PH.101
CT evaluation of mediastinal structures. CT provides detailed
imaging within the mediastinum and may demonstrate find-
ings that give information as to the etiology or severity of
PH. Dilatation of bronchial arteries is a common finding in
CTEPH, but less common in other forms of PH.97,112 A
dilated esophagus in the setting of PH suggests the diagnosis
of systemic sclerosis. Other mediastinal findings, while not
specific to a given etiology, may suggest a poor prognosis.
These include the presence of pericardial effusion, lymph-
adenopathy, and reflux of contrast into the hepatic veins.38
1.5 Magnetic resonance imaging
Summary statements
1. MRI enables comprehensive cardiac evaluation in
patients with suspected PH.
2. MRI is the gold standard technique for the assessment of
biventricular morphology and function and is highly suit-
able for monitoring patients with PH.
3. MRI provides prognostic value in PAH.
4. MRI aids the classification of PH particularly for left
heart disease and chronic thromboembolic disease.
Cardiac MRI is the gold standard for quantification of RV
volumes, mass, function, and flow hemodynamics in the pul-
monary circulation.113,114 Cardiac MRI techniques allow for
non-invasive assessment of RV function and structure using
high spatiotemporal resolution imaging sequences with high
accuracy and reproducibility without exposure to radi-
ation.113 Furthermore, cardiac MRI can be used for assess-
ment of myocardial tissue deformation properties (strain),
global structural evaluation, and perfusion.115–117
Right ventricular size and function. RV hypertrophy and dila-
tion reflect an increased afterload.5 In particular, in
advanced stages of PH, a severely dilated and functionally
compromised right ventricle has a negative effect on LV
diastolic function by means of leftward septal shift and
reduced LV filling associated with decreased RV stroke
volume. Indeed, both RV and LV dimensional metrics
have been shown to have diagnostic potential in treat-
ment-naı̈ve patients with PH and prognostic value in both
adult and child populations.118–120 MRI-derived bi-ventricu-
lar functional and volumetric indices have been shown to
have independent prognostic potential and differentiated
incidental treatment-naı̈ve and prevalent patients in a large
group of patients (n¼ 576).121 Cine MRI derived indices
including interventricular septal bowing, LV eccentricity,
and ventricular dyssynchrony due to prolonged RV contrac-
tion time have been shown to correlate with invasive hemo-
dynamics and are reflective of the overall hemodynamic
condition and disease severity.122,123 Septal deviation mea-
sured by MRI is useful for the diagnosis of PH, but also in
patients with left heart disease septal deviation> 160 can
identify patients with elevated diastolic pulmonary gradi-
ent.124 In addition, MRI has proven useful in the diagnosis
of PH in patients with chronic obstructive pulmonary
disease (COPD), typically a challenging cohort for
echocardiography.125
Late gadolinium enhancement and T1 mapping. Late gadolinium
enhancement (LGE) imaging is used to identify focal myo-
cardial pathology but has also been applied to investigate
regional myocardial disease in the right ventricle as a
response to elevated mechanical stress. The predominant
focus has been on the RV free wall insertion sites to
septum and how the extent of LGE corresponds to RV mor-
phological and dynamic changes.44,45,126–130 Specifically,
LGE was correlated with the reduced RV function, dilation,
mass, and regionally specific LGE was also inversely asso-
ciated with reduced longitudinal strain.128,131 Additionally,
the presence of delayed enhancement at the RV insertion
points has been associated with clinical worsening,127
though in a study using mortality as the endpoint, RV inser-
tion point LGE was not of independent prognostic signifi-
cance. Extension of the LGE into the interventricular
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septum was of prognostic significance at univariate ana-
lysis but was not significant at multivariate analysis.45 A
limited number of studies have explored the role of coronary
arterial flow in PH.117,132 Features may be seen in patients
with PH with LGE imaging; however, its utility in the rou-
tine assessment of suspected PH is not proven. LGE imaging
can be considered where intrinsic cardiac disease is
suspected.
T1 mapping is a quantitative method of assessing myo-
cardial health. Native T1 mapping is performed without the
use of contrast agents and has been shown to be an excellent
differentiator between a healthy and diseased myocar-
dium.133 T1 has been shown to be elevated at the insertion
points in PH in animal134 and human studies.135–137 T1 cor-
relates with markers of RV remodeling135 and septal pos-
ition;138 however, no clear diagnostic or prognostic role has
been identified in PH.138
Right ventricular strain. Myocardial tissue deformation ana-
lysis has been assessed in patients with PH.139–141 RV
morphology limits myocardial tagging and feature tracking
to global longitudinal and circumferential deformation ana-
lysis. MRI-based feature tracking has been shown to have
prognostic potential and was associated with the severity of
PH.142 Measuring LV strain and torsion using tag MRI as
part of ventricular interdependency and dyssynchrony inves-
tigations in CTEPH revealed left–right ventricular resyn-
chronization post endarterectomy.143 However, the clinical
utility of deformation analysis is yet to be determined.
Pulmonary artery and aortic flow measurements. Phase-contrast
MRI (PC-MRI) enables assessment of flow waveform in
major vessels and allows for accurate Qp:Qs assessment,
necessary in patients with suspected congenital lesions.114
Phase-contrast MRI of pulmonary flow is recommended
for assessment of RV stroke volume due to variable tricus-
pid regurgitation and the challenges of contouring the right
ventricle.144 Relative area change of the PA has been shown
to be of clinical value,145,146 and recently has been shown to
be independent of RV measurements and clinical data.37
Black blood slow flow has been shown to be a strong diag-
nostic marker as the flow characteristics of the main and
branch vessels are visualized.147,148 Four-dimensional flow
MRI (4D-Flow MRI) is an emerging technique allowing
evaluation of flow, vorticity, and kinetic energy in any
region of interest. Vortices have been noted in the main
PA of patients with PH. The lifetime of the existence of a
vortex has been shown to correlate with mPAP and may
have utility in the identification of PH.149–152 4D flow also
has the additional benefit that it allows retrospective flow
evaluation by selecting a 2D slice in any plane of the 4D
dataset,153 whereas current techniques rely on the slice pos-
itioning at the time of the scan.
3D MR perfusion and angiography. MR angiography (MRA)
can show characteristic vessel patterns in subtypes of PH,
including pruning in IPAH, thromboembolic obstruction
and stenosis in CTEPH, and splayed vessels in COPD/
emphysema.113 MRA is useful for the assessment of chronic
embolus in the lobar and segmental PA vessels. Beyond the
segmental level, assessment of the PAs with MRA is very
challenging.96 In addition, a central embolus, particularly a
wall adherent clot, can be missed if MRA is reviewed in
isolation; standard white blood MRI sequences can assist
with visualization of a central clot.96
Dynamic contrast-enhanced MRI perfusion is a promis-
ing technique for the assessment of chronic thromboembolic
disease allowing visualization of pulmonary perfusion
defects with sensitivity and specificity similar to that
achieved with SPECT,39 with the advantages of higher spa-
tial resolution and lack of ionizing radiation. Time-resolved
MRA or dynamic contrast-enhanced (DCE) imaging can be
used to measure passage of contrast bolus through the heart
and lungs to assess pulmonary perfusion.154,155 This can be
used to measure mean transit time, time to peak, and blood
volume.152,156,157
1.6 Imaging in conjunction with invasive techniques
Summary statements
1. Catheter-based angiography is used primarily to assess
patients with CTEPH considered as potential candidates
for pulmonary endarterectomy or BPA.
2. Performance of catheter-based angiography requires
skilled operators and should generally be performed in
a PH referral center.
3. Non-invasive imaging approaches can be used to select
patients for pulmonary endarterectomy.
4. Imaging measurements combined with catheter measure-
ments may be used to study RV pressure and volume
relationships.
Digital subtraction angiography. Catheter-based angiography
involves rapid imaging of the PAs during the injection of
contrast material through a catheter placed into the pul-
monary arterial system.158,159 This used to be the primary
method for evaluation of the pulmonary vasculature.
However, given the development of CT and MR methods,
these modalities can also be used.96,106,160 Catheter-based
angiography may be used at expert institutions for the
evaluation of chronic thromboembolism before pulmonary
endarterectomy and is required for BPA.
Assessment of ventricular-arterial coupling. Imaging can be incor-
porated with invasive catheter-based methods for character-
ization of the mechanics of the right ventricle and the
pulmonary arteries. Flow and volumetric MRI measure-
ments in conjunction with pressures obtained from RHC
can be used for assessment of ventricular-arterial cou-
pling.161–163 One method for determining RV contractility
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involves computation of the pressure-volume loop while
using balloon occlusion of the inferior vena cava, permitting
a preload independent assessment of ventricular contractil-
ity.164 In practice, this method requires use of conductance
catheters or the measurement of pressure and flow at the
same time in order to construct the pressure volume loops
with different degrees of preload modulated by the occlusion
of the inferior vena cava. Conductance catheters typically
require calibration of the volume signal from imaging, typ-
ically a baseline cardiac MRI. The ‘‘Single Beat’’ method
using a cardiac catheter can be used to estimate Pmax. This
has been used in conjunction with MRI to measure ventricu-
lar volumes and can serve as a surrogate for Ees/Ea,165 the
relative utility of information from these methods remains
an area of research.166 Cardiac MRI has been used to meas-
ure stroke volume and RV volumes and in conjunction with
pressure measurements to construct pressure-volume loops
and estimate RV contractility.167–170 An entirely MRI-based
non-invasive method of measuring RV to PA coupling has
been proposed, defined by RV stroke volume/RV end-sys-
tolic volume; however, this holds similar information to
RVEF (right ventricular stroke volume / right ventricular
end-diastolic volume).171 Studies have suggested added
prognostic value of coupling measurements,172,173 although
a recent large study suggested it did not add additional prog-
nostic significance over RV volume alone in patients with
PAH.121
Section 2: Imaging adults with pulmonary
hypertension
2.1 The accuracy of cross-sectional imaging to diagnose
pulmonary hypertension and assess pulmonary
hemodynamics
Summary statements
1. A number of CT and MRI findings are characteristic of
PH.
2. Current qualitative approaches to imaging cannot be
used to confidently exclude the presence of PH.
3. Quantitative data obtained from imaging can be used to
diagnose PH and estimate pulmonary hemodynamics.
CT imaging is widely available and measurement of the
PA size has been shown to correlate with mPAP;174 how-
ever, in established PH, there are progressive increases in PA
size over time.175 Pulmonary artery enlargement may
be seen in interstitial lung disease in the absence of PH,94
although a recent publication has shown equivalent diagnos-
tic accuracy in patients with and without interstitial
lung disease. In patients with systemic sclerosis in the
absence of interstitial lung disease, a ratio of main PA
to Ao diameter of at least 1 was highly predictive of
the presence of PAH although a normal ratio did not
exclude PAH.176
MRI is non-invasive, reproducible, and is considered the
gold standard for assessing RV function.177 Studies have
shown a high correlation between RV mass and ventricular
mass index (VMI), the ratio of right-to-left ventricular mass,
and mPAP pressure measured at cardiac catheteriza-
tion.178,179 Recently investigators have shown that combin-
ing VMI and septal curvature improves the accuracy of
estimating mPAP.180 By using MRI to calculate left atrial
volume, pulmonary arterial wedge pressure (PAWP) can be
estimated allowing calculation of the trans-pulmonary gra-
dient.180 Cardiac output can be calculated from LV volu-
metric measurements or phase contrast of flow in the PA or
Ao allowing an entirely non-invasive estimate of pulmonary
vascular resistance (PVR) based on individually derived
MRI measurements. Models using RVEF and average PA
velocity have also demonstrated accuracy for estimating
catheter-derived PVR.181 Studies comparing cardiac mag-
netic resonance cardiac MRI and RHC in patients suspected
of PH have shown that an elevated VMI, reduced PA vel-
ocity, and the presence of increased gadolinium at the hinge
points could predict the presence of PH with a positive pre-
dictive value of >0.9 although no cardiac MRI measure
could confidently exclude PH.179 In summary, although
able to estimate pulmonary hemodynamics and identify
PH with high accuracy in certain groups, imaging is cur-
rently unable to exclude PH.
2.2 How helpful is imaging in identifying the cause of
pulmonary hypertension and subtyping?
Summary statements
1. Different forms of PH and their subtypes may exhibit
characteristic imaging features.
2. Echocardiography and MRI are useful for differentiation
of pre and post capillary PH.
3. CT provides an accurate evaluation of lung structural
abnormalities.
4. Nuclear medicine, CT and MR perfusion imaging can be
used to exclude chronic thromboembolic disease.
5. Different combinations of imaging modalities can be
employed tailored to local expertise and availability.
Many of the imaging findings associated with PH are
common to most or all disease processes leading to PH.
These findings may include enlargement of the central
PAs, right-sided cardiac enlargement, and abnormalities of
lung attenuation. Some imaging findings, however, are more
specific and can help to distinguish among the various
causes of PH. These are discussed in the following section.
Pulmonary arterial hypertension (group 1). Within group 1 PAH,
imaging findings may suggest a specific etiology. Patients
with systemic sclerosis typically have a dilated esophagus,
a central ground glass pattern, and often associated intersti-
tial lung disease. Drug and toxin exposures may also be
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associated with mild parenchymal fibrosis or mosaic lung
attenuation. In patients with portopulmonary hypertension,
the presence of varices, features of liver cirrhosis, and
splenomegaly are frequent. Anomalous pulmonary venous
drainage should be sought as this is frequently associated
with congenital heart disease, in particular a sinus venosus
atrial septal defect which is difficult to detect by transthor-
acic echocardiography. An interatrial shunt may also be
suggested by contrast visualized entering the left atrium
via the interatrial septum. While enlargement of the PAs is
common to all forms of PAH, it is greatest in patients with
Eisenmenger physiology.38 Patients with Eisenmenger physi-
ology may also have laminated proximal thrombus and cal-
cification within the wall of the PA. Bronchial artery
enlargement is most frequently observed in CTEPH but is
also observed in patients with congenital heart disease182
and patients with IPAH and a BMPR-2 mutation.183
PVOD is rare and is characterized by mediastinal lymph-
adenopathy and interlobular septal thickening,184,185 with or
without associated findings of alveolar edema, mediastinal
lymphadenopathy in the setting of a normal sized left
atrium. PCH is frequently associated with nodular foci of
parenchymal infiltration. The triad of peripheral interlobu-
lar septal thickening, centrilobular ground-glass opacities,
and mediastinal lymphadenopathy has a good association
with PVOD and PCH.184,186,187
Pulmonary hypertension due to left heart disease (group 2), pulmon-
ary hypertension due to lung diseases (group 3), and pulmonary
hypertension with unclear and/or multifactorial mechanisms (group
5). Within these groups, imaging may be useful to identify
either left-sided cardiac enlargement (group 2) or diffuse
lung disease (groups 3 or 5). Many lung diseases will have
a distinctive radiographic appearance allowing for specific
diagnosis and grading of severity. Characteristic structural
features of patients with left heart disease which can be
visualized on both CT and MRI include left atrial enlarge-
ment,188–190 absence of posterior displacement of the inter-
ventricular septum,179 and relatively normal RV volumes,
although RV enlargement is seen in more severe disease par-
ticularly in the setting of severe tricuspid regurgitation. The
presence of valvular and coronary artery calcification and
evidence of previous cardiac surgery are more common in
left heart disease although may also be present in patients
with other forms of PH. Echocardiography and MRI allow
a comprehensive functional assessment. Patients with left
heart disease have less RV hypertrophy and compared to
pre-capillary forms of PH have better preserved RV func-
tion. The absence of paradoxical septal motion/septal dis-
placement in the setting of high right-sided pressures infers
an increase in left-sided pressures. Echocardiography allows
assessment of both systolic and diastolic dysfunction and
the identification of valvular heart disease, in addition to
identifying features suggestive of combined post- and pre-
capillary disease.191
Chronic thromboembolic pulmonary hypertension (CTEPH) and other
pulmonary artery obstruction (group 4). A large prospective
study estimated the risk of developing CTEPH after a pul-
monary embolism at 3.8% at two years.192 Imaging plays a
critical role in the evaluation of suspected CTEPH, although
the exact role of each imaging modality is debated. Some of
this uncertainty reflects the rapid development of imaging
technologies. Chest radiographs may suggest the diagnosis
of CTEPH – with cardiomegaly, asymmetrical pulmonary
artery enlargement, pruning of the vasculature and sub-
pleural scarring; however, they are not diagnostic.
Historically decisions on diagnosis and surgical manage-
ment were based on V/Q scintigraphy and conventional
pulmonary angiography with RHC. The role of V/Q scin-
tigraphy (either planar or SPECT imaging) has changed.
SPECT is recommended over planar imaging as it has
higher diagnostic accuracy.193
The current ESC/ERS guidelines recommend that V/Q
scintigraphy be performed in all patients with suspected
CTEPH.194 These recommendations for V/Q scanning are
in part based on clinical experience, previous recommenda-
tions, and on older data.195–197 These data demonstrated a
significant improvement in the detection of CTEPH with
scintigraphy compared to CTPA. However, rapid develop-
ments in CT technology have led to marked improvement in
disease detection and characterization. More recent studies
in experienced centers demonstrate that CTPA has high
diagnostic accuracy for CTEPH.39 Key imaging findings
include identification of eccentric thrombus, intravascular
webs, stenoses with or without post-stenotic dilatation,
and occlusions. Bronchial artery dilatation (commonly
described as a diameter of >2mm) is more commonly seen
than in other forms of PH. The presence of bronchial artery
dilatation is associated with a better outcome following pul-
monary endarterectomy. A mosaic perfusion pattern is seen
in the vast majority of patients with CTEPH. Its presence
should alert the observer to the possibility of CTEPH but
should be differentiated from the mosaic pattern seen in
small airways disease where often single or small clusters
of lobules are involved in contrast to larger geographical
areas typically seen in CTEPH. Performance of expiratory
CT may be helpful in this setting. Peripheral areas of sub-
pleural scarring and cavitation representing healed infarcts
may also be seen in approximately 10% of patients with
CTEPH.198 DECT imaging generates maps of regional
iodine density in the lung parenchyma as a surrogate for
perfusion. This may further improve the evaluation of sus-
pected CTEPH by better demonstrating regions of
decreased or absent blood flow199 and has been shown to
have excellent agreement with SPECT.200 Although the
availability of this technology is relatively limited, iodine
mapping using CTPA with an unenhanced pre-scan is an
emerging technique, which generates a lung perfusion
map. In contrast to DECT, it does not require specialized
hardware but involves subtraction of unenhanced images
from the contrast-enhanced study. This has the advantage
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that subtle abnormalities that may be missed on the angiog-
raphy are unlikely to be overlooked on a perfusion map thus
improving detection of subtle webs and distal disease.81
By providing an assessment of the lung parenchyma and
the mediastinum CT can be helpful in identifying the pres-
ence of diffuse lung diseases and emphysema (groups 3 and
5) and excluding pulmonary vascular obstruction from a
central mass. Parenchymal evaluation may also be valuable
in identifying features suggestive of interstitial edema,
PVOD, or vasculopathy though there is overlap in the ima-
ging features. CT may also identify features suggestive of
large vessel vasculitis or PA sarcoma which may not be
readily appreciated on projectional angiography.
MRI can also provide an evaluation of the pulmonary
vasculature and is increasingly being used in select centers
for the evaluation of known or suspected CTEPH. 4D DCE
lung perfusion MRI techniques201 are widely available on
current MRI systems and have shown excellent test per-
formance in diagnosing CTEPH in a single center registry
setting.39 In addition, a non-contrast, free-breathing venti-
lation perfusion MRI technique, known as the Fourier
Decomposition (FD)-MRI method202,203 has recently
shown initial encouraging results in diagnosing chronic pul-
monary embolism;204 however, this technique needs to be
confirmed in larger multicenter studies. Combined
cardiac MRI and time-resolved MRA exam is suitable for
detailed treatment response evaluation before and after pul-
monary endarterectomy as well as BPA in CTEPH
patients.205,206
CTPA has largely replaced invasive catheter-based angi-
ography as the initial morphological test for PA evaluation
in most centers. However, catheter-based angiography may
still have a role in the evaluation of CTEPH. Older data
suggest that catheter-based angiography may provide a
better assessment of the extent of pulmonary vascular
obstruction than V/Q scintigraphy.207 Additionally, some
expert centers prefer catheter-based angiography for evalu-
ation of the extent of thrombotic disease before PEA.208
Again, CT performance relative to catheter-based angiog-
raphy is generally poorer in older studies159 compared to
more recent data.209,210 This difference again likely reflects
significant advances in CT technique and technology as well
as greater awareness of CTEPH and its imaging features in
imaging circles. When there is diagnostic uncertainty regard-
ing the extent and distribution of chronic thromboembolic
changes on the basis of a single imaging modality
(usually CT), the use of a second morphologic imaging
modality (MRA or catheter-based angiography) may
prove complementary by improving confidence in subtle
lesions or identifying others. This can augment surgical
decision-making.
In recent years, BPA has emerged as an effective thera-
peutic modality in selected patients with CTEPH. This has
put greater emphasis on the evaluation of distal segmental
and subsegmental vasculature. It is generally considered that
at the subsegmental level, catheter-based angiography
outperforms non-invasive morphological techniques (CT/
MRI) which has resulted in increased utilization. Clinical
criteria and imaging algorithms for the selection of patients
for BPA vary between centers but catheter-based diagnostic
angiography for potentially suitable candidates permits con-
firmation of suitable extent and distribution of disease as
well as the patients ability to tolerate a BPA procedure (abil-
ity to maintain breath-hold and tolerate the required period
on the catheter table).211
2.3 Echocardiography and cardiac MR: what are the
advantages and disadvantages of each modality?
Summary statements
1. Echocardiography is more widely available, lower in cost,
and more portable than MRI.
2. Echocardiography is superior to MRI for the evaluation
of valvular heart disease and is more established in the
assessment of diastolic function.
3. MRI provides more accurate quantitative assessment of
RV morphology and function.
4. MRI is more suited to serial assessment than echocardi-
ography due to higher reproducibility.
Echocardiography and cardiac MRI provide value in the
assessment of patients with PH. Echocardiography is well
established in the initial assessment of patients with sus-
pected PH. It has also been evaluated in the serial assess-
ment of patients with PH66,67 and has been found to be
prognostic and is recommended in current guidelines at
follow-up and following treatment change.
Technical factors. Echocardiography has high temporal reso-
lution, is widely available, low in cost, portable, and less
affected by arrhythmia than MRI although real-time ima-
ging212 has helped to counter this limitation at the cost of
lower spatial resolution. Echocardiography is more opera-
tor-dependent and is less reproducible. MRI has the advan-
tage that it has better contrast resolution and is able to
image in any plane making it more suited to accurately
quantify RV morphology and function. Furthermore,
contrast imaging allows assessment of focal abnormalities
of the myocardium and an assessment of myocardial
perfusion.113,116
Estimation of pulmonary hemodynamics. In a systematic review
of the literature, the sensitivity and specificity for echocar-
diography for diagnosing PH was 83% (95% confidence
interval [CI]¼ 73–90) and 72% (95% CI¼ 53–85), respect-
ively. However, echocardiography is less accurate, in lung
disease with sensitivity of 60% and specificity of 74%.213
Empiric approaches have been used to estimate pulmonary
hemodynamics using MRI.178,180 In a recent study, mPAP
was accurately estimated using multivariate regression ana-
lysis of MRI indices, with ventricular mass index and
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interventricular septal angle having additive value in model
for estimation of mPAP.180 It has recently been shown that
with the inclusion of black blood pulmonary arterial slow
flow in addition to ventricular mass index and interventri-
cular septal angle high diagnostic accuracy can be improved
further.147
Right ventricular volumetric and functional assessment. Complete
visualization of the right ventricle with echocardiography
can be challenging, particularly in lung disease, preventing
a complete volumetric evaluation of the right ventricle; this
may be partially negated by the use of 3D echocardiog-
raphy. MRI has the advantage of complete volumetric
evaluation of the cardiac chambers with good reproducibil-
ity of volume, mass, and ejection fraction214 and is con-
sidered the gold standard for serial assessment of RV
volume and function.215 Inaccuracies in segmentation of
the right ventricle at the base of the heart and segmentation
of ventricular trabeculations may be improved using thresh-
old-based approaches.
Echocardiography, using pulsed wave and tissue
Doppler, is an established technique for the assessment of
diastolic function. MRI phase contrast evaluation of the
mitral annulus is feasible216 and in a small study imaging
of the mitral valve annulus, in combination with mitral valve
and pulmonary venous flow, was as accurate as echocardi-
ography.217 Other techniques such as myocardial SPAMM
tagging218 and 4D three-directional velocity encoded
MRI219 have been used to evaluate LV diastolic function.
Long analysis times may reduce the applicability for routine
clinical use.
Valvular heart disease. PH may occur in the setting of valvular
heart disease. Echocardiography is the most useful non-
invasive technique and has the advantage over MRI in
that it has high temporal resolution and allows accurate
quantification of the severity of valvular heart disease.
Left-sided valvular heart disease is a common cause of
group 2 PH. Contemporary studies suggest a prevalence
of PH of 30–40% in patients with mitral stenosis220 upwards
of 30% in patients with severe mitral regurgitation;221 in
asymptomatic patients, the presence of PH serves as an indi-
cation for valve surgery.222 With the emergence of trans-
catheter aortic valve replacement, PH has been noted in
up to 75% of patients with severe aortic stenosis.223
Currently, echocardiography is the recommended non-inva-
sive technique for the assessment of the presence and sever-
ity of valvular disease given its advantages over MRI
including availability, low cost, high temporal resolution,
and widespread experience over many years. Despite this,
there are instances in which echo is limited due to poor
acoustic windows, lack of agreement across quantitative
methods, and significant inter- and intra-observer variabil-
ity, which has led to interest in the emerging role of MRI in
the assessment of valvular heart disease.224,225
2.4 Can imaging replace cardiac catheterization in the
assessment of suspected pulmonary hypertension?
Summary statements
1. Cardiac catheterization is the gold standard for the meas-
urement of PAP.
2. CT and MRI may suggest the diagnosis of PH and quan-
titative MRI metrics can be used to confirm the presence
of PH with high accuracy.
3. At diagnosis MRI and cardiac catheterization provide
equivalent levels of prognostic information.
4. Cardiac catheterization is currently the only way to iden-
tify patients with IPAH likely to benefit from calcium
antagonist therapy.
Current ESC/ERS guidelines226 recommend RHC for the
definitive diagnosis of PH, assessment of intra-cardiac
shunting, and vasodilator testing in selected patients to iden-
tify the 10% of patients with IPAH who may benefit from
high-dose calcium antagonist therapy. Measurements such
as right atrial pressure, cardiac index, and mixed venous
oxygen saturation have prognostic value,227–229 and serial
measurements are currently recommended to assess the
response to therapy.226 The procedure requires meticulous
attention to detail but in expert hands is safe in adults with a
morbidity of approximately 1% and mortality of 0.055%,230
although the risk of complications is significantly higher in
children. Well established criteria at right heart catheter
exist to assess patients with IPAH likely to benefit from
calcium antagonist therapy. However, no such criteria
exist for imaging metrics.
Although current guidelines discuss the role of CT and
MRI in the classification of PH, they are currently con-
sidered an adjunct and not yet considered a replacement
for RHC.
2.5 What is the role of imaging in assessing prognosis
and response to treatment?
Summary statements
1. Echocardiography allows assessment of RV function and
measurements such as right atrial area, RV fractional
area change, and tricuspid annular plane systolic excur-
sion have prognostic value.
2. CT imaging provides prognostic information in PAH but
its role in follow-up is currently limited by exposure to
radiation.
3. A number of cardiac MRI metrics have prognostic value
and changes in cardiac MRI parameters at follow-up
reflect changes in functional capacity and survival.
4. Adjustment of RV functional measurements for age and
sex improves prognostication.
5. Changes in RV function measured by MRI have prog-
nostic value.
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Echocardiography is widely available and a number of met-
rics have been shown to have prognostic value including
right atrial area,231 RV fractional area change,
TAPSE,232–234 and the presence of a pericardial effu-
sion.231,235 Echocardiography is widely used, in many cen-
ters to assess the response to treatment, acknowledging
issues of operator-dependency and reproducibility.
Several measurements made at CTPA—including RV to
LV ratio, right atrial size, and a posteriorly deviated inter-
ventricular septum—predict prognosis in PAH subgroups
while the presence of pleural effusions, septal lines, and
increased inferior vena cava area were independent pre-
dictors of a worse outcome in PAH at presentation regard-
less of subgroup.38 Although this may be helpful at
presentation to guide urgent assessment and introduction
of emergency therapies, the availability of other imaging
modalities and associated radiation exposure necessitates
that CT is not recommended in the assessment of treatment
response.
In contrast, the highly reproducible nature and non-inva-
sive and non-ionizing nature of MRI makes it an ideal
modality to assess treatment response and in the EURO-
MR study236 changes in MRI measured cardiac index and
RV RVEF correlated with changes in World Health
Organization functional class and survival. A study examin-
ing changes in cardiac MRI parameters demonstrated that
this was a better predictor of outcome than PVR measured
invasively at cardiac catheterization.215 MRI metrics includ-
ing increased RV volumes, reduced LV volumes, stroke
volume, cardiac output, and pulsatility of the vasculature
predict a worse outcome in PAH although there is currently
no large study comparing the prognostic value of cardiac
MRI and right heart catheter measures.
2.6 How can we improve imaging techniques to make
them more acceptable to patients?
Summary statements
1. Minimizing radiation dose by the use of non-ionizing
techniques where possible and implementation of dose
reduction protocols will reduce the risks to patients.
2. Involvement of patients in investigative decision-making
will allow a more tailored approach to investigation.
While plain chest radiographs and echocardiography are
generally well-tolerated and acceptable examinations,
cross-sectional techniques do have some specific limitations
and issues, in particular radiation doses for CT and claus-
trophobia for MRI.
The diagnostic information provided by CT needs to be
balanced with the radiation dose. In a life-shortening illness,
concerns regarding radiation exposure rarely impact on the
decision to perform CT imaging at the time of diagnosis.
Advances in dynamic imaging, with improved temporal
resolution, has provided hope that gated CT can challenge
MRI in the assessment of cardiac function; however, such
examinations typically involve higher doses of radiation.
Using iterative reconstruction, dose reduction can be
achieved.237 In fact, large reductions in dose to less than
one-third the dose of standard acquisitions have been
achieved without loss of image quality using iterative recon-
struction,238 and the use of dynamic Z axis collimation has
been shown to further reduce dose.239
Limitations of MRI include long scanning times and
scanner noise, and frequently patients feel claustrophobic
(5%) leading to incomplete examinations. Developments
to reduce scanning time, e.g. novel rapid imaging tech-
niques, and limiting the study to the most clinically relevant
sequences may help. The more widespread installation of
wide bore scanners may help to reduce claustrophobia and
make MRI a more acceptable imaging modality for all
patients. The use of media entertainment may improve
acceptability to patients. More patient involvement in dis-
cussions around the implications of the tests are needed.
Patient participation is advised to determine the issues
most relevant to patients to help develop imaging services.
Section 3 Imaging pathway for suspected
pulmonary hypertension in adults
3.1 Current guidelines
The ESC/ERS guideline on diagnostics and therapy of PH
review current imaging modalities and make a number of
recommendations for incorporation in a diagnostic strat-
egy.2 Echocardiography is recommended as a first-line
non-invasive diagnostic investigation in case of suspicion
of PH. Chest X-ray and high-resolution CT are recom-
mended in patients with high or intermediate probability
of PH following echocardiography and high-resolution CT
should be considered in all patients with PH. Ventilation/
perfusion or perfusion lung scan is recommended in patients
with unexplained PH to exclude CTEPH. Contrast CT angi-
ography of the PA circulation is recommended and pulmon-
ary (catheter-based) angiography should be considered in
the work-up of patients with CTEPH. There are no recom-
mendations for the use of MRI as part of the diagnostic
strategy or algorithm and no discussion of emerging tech-
niques.240,241 Current American College of Chest Physicians
guidelines on PH provide no specific recommendations on
employing imaging as part of a diagnostic strategy in
patients with suspected PH.242
The Cologne Consensus Conference 2016 provides no
additional imaging guidelines.
3.2 PVRI diagnostic imaging pathway
Initial assessment and identification of risk factors. In patients
presenting with symptoms and/or signs suggestive of PH,
a detailed history and the results of basic tests are key in
determining the diagnostic strategy (Fig. 1). Risk factors for
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treatable forms of PH (PAH and CTEPH) must be
sought as their presence reduces the threshold for further
imaging. Basic investigations including an electrocardio-
gram, lung function with gas transfer factor, and a plain
radiography may suggest an alternative diagnosis194 or
increase the probability of PH. Further investigation may
not be required when a confident alternative diagnosis can
be made.
Echocardiograpy. Echocardiography is the recommended first-
line imaging modality in the assessment of suspected PH
and allows evaluation of cardiac structure and function
and an estimate of PAP. Following echocardiography,
patients should be stratified into those at low, high, or inter-
mediate probability of PH according to ESC/ERS guide-
lines.194 Where patients have rapidly progressive symptoms
and a high probability of PH from echocardiography, phys-
icians should not delay referral to expert centers until the
above investigations are completed.
Sub-optimal echocardiography. For patients with a sub-optimal
echocardiogram, imaging with cardiac MRI can be used to
identify patients at increased risk of PH although currently
used metrics cannot confidently exclude mild PH.147 A
number of metrics on CTPA have been shown to reflect
elevated PAPs in addition to providing information on
other potential causes for breathlessness; although evidence
is limited, this may be considered in selected patients.91,95
Low probability of pulmonary hypertension from
echocardiography. For symptomatic patients identified as
low probability from echocardiography, further assessment
is dependent on the presence or absence of risk factors. For
those with risk factors for CTEPH, perfusion lung imaging
is recommended using CT imaging (CT-LSIM of DECTA),
nuclear medicine techniques (ideally SPECT), or MRI per-
fusion imaging.39,81,86,243 If risk factors for PAH exist, the
diagnostic strategy will be dependent on the risk factor; in
systemic sclerosis, given the high prevalence of PAH in
symptomatic patients, further evaluation is advised and a
Fig. 1. PVRI diagnostic algorithm. In this algorithm, patients are classified into low, intermediate, and high risk of PH according to ESC/ERS
guidelines.2 See section 3.2 for a detailed description of how to navigate the algorithm. *For patients with rapidly progressive symptoms
and a high probability of PH on echocardiography do not delay referral to PH centre to complete imaging investigations. PH,
pulmonary hypertension; PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary hypertension; ECG, electrocar-
diogram; DLco, diffusing capacity of the lungs for carbon monoxide; CXR, chest radiograph; CMRI, cardiac magnetic resonance imaging; CTPA,
computed tomography pulmonary angiography; DECTA, dual-energy computed tomography angiography; CT-LISM, computed tomography lung
iodine subtraction mapping; SPECT, single photon emission computed tomography; RV, right ventricular.
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number of screening regimens exist such as DETECT.244
For other at-risk patients, an interval echocardiographic
examination may be appropriate.194
High or intermediate probability of pulmonary hypertension from
echocardiography and assessment for left heart disease. For
patients with intermediate or high probability of PH, the
echocardiogram should be evaluated for evidence of left
heart disease such as significant valvular heart disease, LV
systolic or diastolic dysfunction. If present, the history
should be re-reviewed to assess for risk factors for left
heart disease (hypertension, obesity, coronary artery dis-
ease, diabetes mellitus, atrial fibrillation). Where risk factors
for PAH or CTEPH are absent and risk factors for left heart
disease present, PAP modestly elevated, left atrial size
increased, no paradoxical septal motion, and/or significant
RV dysfunction present, then no further investigation to
assess for PH may be required. However, where risk factors
for PAH or CTEPH are present, RV function is severely
impaired, systolic PAP is severely elevated (70mmHg),
and/or paradoxical septal motion exists, then further inves-
tigation to exclude other causes of PH should be con-
sidered.26 If no features of left heart disease exist, patients
should undergo CT pulmonary angiography if no contra-
indications exist.
CT pulmonary angiography. Where left heart disease is
excluded, or if present and other causes of PH cannot be
confidently excluded, then cross-sectional imaging with CT
including CT pulmonary angiography should be considered
as it can aid in: (1) assessment of the likelihood of PH; (2)
classification of disease (identifying features of co-existing
lung disease or left heart disease); and (3) identification of
patients with CTEPH.38 If features of CTEPH are identified
at this stage, patients should be referred directly to a center
experienced in the management of PH for further
evaluation.
Perfusion lung imaging. If CTPA is sub-optimal, indetermin-
ate, or is performed by a center not experienced in the
assessment of PH and CTEPH is not identified, in the
absence of significant parenchymal lung disease, perfusion
lung imaging (Q-SPECT of 3D MR perfusion) is advised at
this stage. CT lung subtraction iodine mapping (CT-LISM)
or DECT in addition to directly visualizing abnormalities in
the pulmonary arterial tree also allows construction of per-
fusion lung maps, preventing the need for other forms of
perfusion lung imaging to exclude CTEPH.81,86,199,245
Supplementary investigations including tests to assess for
conditions associated with PAH such as connective tissue
disease and HIV infection should be considered.1,194
Review and integration of imaging investigations with other tests and
assessment for respiratory disease. Following imaging, the
results should be integrated with the patient’s clinical char-
acteristics. CT imaging may identify unexpected findings
such as thromboembolic disease or parenchymal lung dis-
ease. Given the current lack of evidence for specific inter-
ventions targeting the pulmonary vasculature for patients
with PH in the context of respiratory disease current thera-
pies should be aimed at the underlying condition, recogniz-
ing that the presence of PH identifies patients at increased
risk of death; where appropriate options such as transplant-
ation should be explored. In patients with respiratory dis-
ease with risk factors for PAH or CTEPH, significant RV
dysfunction or severe elevation in systolic PAP
(70mmHg), referral to a PH center should be considered;
selected patients may be entered into studies or receive a
trial of therapy. In addition to pulmonary vascular phen-
toypes increasingly recognized in respiratory disease,4,246,247
these patients may have other forms of PH such as undiag-
nosed connective tissue disease or CTEPH.247 Where uncer-
tainty exists, discussion or referral to a PH center is
recommended.
Referral or discussion with a pulmonary hypertension referral
center. PH referral centers provide an environment where
specialists are experienced in the assessment of patients
with suspected PH. They also provide specific therapies
and support for people affected by PH. Imaging investiga-
tions will be reviewed and, where sub-optimal, may be
repeated. At this stage, further investigation will usually
be dependent on the pre-test probability of different forms
of PH (Table 1). For patients considered for treatment, car-
diac catheterization is recommended.
CTEPH suspected. For those with evidence of CTEPH on
CTPA or with risk factors such as previous pulmonary
embolus, deep venous thrombosis, splenectomy, or pace-
makers, further evaluation of (1) the pulmonary vasculature
with DSA or MRA, (2) lung perfusion, with SPECT or 3D
MR perfusion, DECTA/CT-LISM, (3) lung ventilation, (4)
biventricular function, with cardiac MRI or 3D echo, and
(5) coronary or further cardiac valvular assessment, if risk
factors for ischemic heart disease exist or co-existant valvu-
lar heart disease is noted, and the patient is considered a
candidate for pulmonary endarterectomy, may be per-
formed. The choice of investigations is also dependent on
the preference of PH referral center, where pulmonary end-
arterectomy or BPA, is being considered. RHC with meas-
urement of PAWP and PVR will aid decisions regarding
appropriateness of the intervention and to confirm the pres-
ence of PH. Where filling defects extend into the proximal
PA and or RV outflow tract, other conditions such as sar-
coma should be considered and FDG-PET-CT may be
helpful.248,249
Patients with risk factors for specific forms of pulmonary
hypertension. In patients with risk factors for specific forms
of PAH, further investigation should be tailored; ultrasound
examination of the liver with portal Doppler ultrasound
should be performed in patients suspected of underlying
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liver disease/portal hypertension. In cases where congenital
heart disease is suspected (features such as anomalous pul-
monary venous drainage or atrial septal defect may have
been detected on CT or transthoracic echocardiography),
transesophageal echocardiography and or cardiac MRI to
estimate Qp:Qs ratio and cardiac catheterization with a sat-
uration run should be considered.250,251 In patients with PH,
where the cause is felt to primarily related to left heart dis-
ease or respiratory disease, RHC may be required to assess
disease severity particularly if a trial of treatment is contem-
plated. Further assessment of RV function in these patients
may be helpful, particularly where the echocardiographic
assessment of RV function was challenging; findings at car-
diac MRI of preserved or mildly impaired RV function or a
normal septal angle in PH-LHD (suggesting the absence of a
pre-capillary component) may negate the need for RHC.124
Unexplained pulmonary hypertension. Where no obvious cause
of PH exists, following review of imaging and integration
with other clinical characteristics, cardiac catheterization
with vasodilator testing should be performed to identify
the 10% of patients with IPAH who have a fall in mPAP
or at least 10mmHg to <40 mmHG with no reduction in
cardiac output, who may respond to treatment with high-
dose calcium channel blockers.194
Unexplained hypoxemia. Hypoxemia in PH is uncommon at
the time of diagnosis in the absence of respiratory disease,
a right-to-left shunt, or a severely reduced gas transfer
factor. If a right-to-left shunt is suspected, a bubble
echocardiogram, renal perfusion SPECT, or MRI (time-
resolved imaging or Qp:Qs) should be considered.
Monitoring of patients at follow-up. Following diagnosis, follow-
up assessments of RV function are recommended to aid
risk stratification119,215 in combination with a clinical assess-
ment and a measurement of exercise capacity. Cardiac MRI
or echocardiography can be used to assess RV function.
In selected cases, follow-up cardiac catheterization may be
performed.
Section 4.0: Imaging children with suspected
pulmonary hypertension
Summary statements
1. Echocardiography is recommended as the initial imaging
investigation in children with suspected PH.
2. Performance of cardiac catheterization in children fre-
quently requires general anesthesia and is associated
with a higher risk of complications than in the adult
population.
3. Diagnostic imaging strategies differ in children compared
to adults reflecting significant differences in disease
etiology.
4. MRI is of additional value in the initial evaluation and
follow-up of PH in conjunction with other non-invasive
techniques such as echocardiography.
5. Imaging techniques should be modified where possible to
provide adequate diagnostic information while avoiding
anesthesia.
Table 1. Recommended imaging investigations in adults with pulmonary hypertension considered for specific pulmonary vascular interventions.
Imaging investigations
All patients Echocardiography
CTPA or DECTA or CT-LSIM
Perfusion lung imaging in selected patients (see section 3.2)
Liver disease suspected or known Ultrasound scan of liver with portal Doppler
Congenital heart disease suspected or known Consider:
MRI with Qp:Qs
Transesophageal echocardiogram
Left heart disease or respiratory disease Cardiac MRI or further echocardiographic studies to assess RV function may reduce
the need to proceed to cardiac catheterization
Suspected CTEPH Consider: MR angiography or digital subtraction angiography
Lung ventilation
If malignant obstruction suspected FDG-PET CT recommended




Follow-up of RV function Echocardiography
Cardiac MRI
CTPA, CT pulmonary angiography; DECTA, dual-energy computed tomography angiography; CT-LSIM, computed tomography lung subtraction iodine mapping;
CMRI, cardiac magnetic resonance imaging; Qp:Qs, pulmonary–systemic flow ratio; FDG-PET CT, fluorodeoxyglucose-positron emission tomography computed
tomography; SPECT, single photon emission computed tomography.
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4.1 Introduction
Imaging provides valuable information that aids the man-
agement of patients with PH, from diagnosis and accurate
phenotyping, through to monitoring disease and assessing
response to therapy. The majority of imaging modalities in
medicine and their implementation in hospital environments
have been developed with the needs of adult patients in
mind. While the underlying philosophy and principles of
imaging in children are the same as in adult PH, there are
some challenges which may be more pertinent to imaging
children. With appropriate modification these can be
overcome.
4.2 Differences in the spectrum of disease between adults and
children. While pulmonary vascular disease pathophysiology
is very similar, the context in which it occurs in children is
often very different to adult cohorts of PH. Most notably,
children are much more likely to have PH in the context of
congenital or developmental abnormalities, whereas in adult
populations co-morbid diseases of aging may be more
important. Large cohorts of pediatric patients with PH dem-
onstrate that PH related to congenital heart disease and PH
related to developmental lung disorders predominate with
IPAH responsible for approximately 20% of published
cohorts and CTEPH responsible for <1% of cases.252
Furthermore, approximately 30% of children with PH
have more than one potentially causal association.253
Finally, in a large proportion of children with PH, the PH
is associated with other rare conditions. Taken together, this
means that the pre-test probabilities of different PH etiolo-
gies differ from that in adults. This, in turn, affects the over-
all diagnostic imaging strategy. A diagnostic algorithm for
children has recently been published following the World
Symposium of Pulmonary Hypertension and reflects differ-
ences between adults and children.254
4.3 Scale. The pediatric period covers a period from birth to
adulthood. The body undergoes enormous growth and
development during this period of time and body size can
increase by almost two orders of magnitude. Organ struc-
ture, function, maturity, and complexity continue to develop
through childhood and again enormously during puberty,
profoundly affecting physiology.
The most obvious change through childhood is in size.
This produces challenges when aiming to distinguish normal
organ size from abnormal, e.g. ventricular volume. A
number of approaches have been adopted to address this
challenge. The first is to establish normative data for chil-
dren throughout childhood and express these in terms of
centile charts or standard deviation (Z) scores. Normative
values in echocardiography in large populations of healthy
children are increasing with normative echocardiographic
values published in pediatrics with Boston z-scores.255,256
Normative values in CMR in large populations of healthy
children is challenging and normative data are sometimes
lacking. A second approach is to adopt ratio–metric
relationships, i.e. the parameter in question is simply divided
by a measure of body size, e.g. body surface area (BSA), or
is expressed as a ratio against another cardiovascular par-
ameter in the same patient, e.g. PA to Ao size ratio; how-
ever, these approaches have significant limitations. A more
appropriate and physiologically sound approach to scaling
may be to adopt allometric scaling relationships. This
approach divides the cardiovascular variable of interest by
the body size variable raised to a scalar exponent in the form
x/yb. There are data across a huge range of scales and spe-
cies which show empirically that this approach eliminates
the effect of body size on cardiovascular structure and func-
tion. This approach to scaling or normalization has not been
widely adopted and therefore the relevant scaling exponents
are not well established or accepted.
The effect of scale on imaging resolution. By definition, in chil-
dren spatial scales of structures are smaller (i.e. children are
smaller) and temporal scales are typically shorter (i.e. chil-
dren have higher respiratory rates and higher heart rates).
This therefore affects imaging quality at any given spatio-
temporal resolution. While some adaptations are possible
for example higher frequency ultrasound probes for echo-
cardiography, other imaging modalities suffer from funda-
mental physical and engineering limits to their spatial
temporal resolution. Table 2 suggests some approaches
which may improve spatiotemporal resolution of imaging
modality such that they are suitable for smaller patients.
4.4 Intellectual/emotional maturity
Many imaging modalities require the cooperation of the
patient to achieve optimal imaging results. Children are
often emotionally and intellectually less mature than
adults; thus, securing their cooperation can be more challen-
ging and time-consuming. One approach to this which is
widely used is to sedate or anesthetize children; however,
sedation and anesthesia in children with PH is associated
with a substantial risk of morbidity and mortality and it is
desirable to avoid this wherever possible. Imaging in an
appropriate environment with adequate time and support,
e.g. play therapist involvement and time to familiarize
patients with the environment, can substantially improve
cooperation and imaging quality. Distraction techniques
and allowing parents into the imaging room are extremely
helpful.
4.5 Echocardiography in pediatric pulmonary
hypertension
Echocardiography is used as the initial screening diagnostic
imaging for the diagnosis of pediatric PH and the most
important non-invasive tool that is used for routine assess-
ment.47,48,252,257–259 It is used for continued follow-up and
medication management.260 Developments in echocardiog-
raphy in the past two decades have led to new insights into
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the structure and function of the right ventricle and its role
in various diseases including PH.261,262 Conventional ima-
ging includes assessment of anatomy in two dimensions
(2D), hemodynamics via Doppler echocardiography, and
qualitative and quantitative evaluation of RV and LV func-
tion.47,48,258,260,263–265 Advanced echocardiography includes
evaluation of right heart size and function, myocardial
mechanics, and estimated RV to PA coupling ratio.266–270
Table 3 shows the advantages and limitations of each of
echocardiographic techniques used in pediatric PH. In
recent years, different echocardiography parameters have
been found in small studies to be useful in identifying
high-risk patients who are likely to develop adverse clinical
outcomes.269,271–274 Table 4 demonstrates the echocardio-
graphic views needed to obtain the functional parameters
in pediatric PH.
4.6 Cardiac magnetic resonance imaging in pediatric
pulmonary hypertension
Cardiac MRI remains the gold standard imaging modality
for assessment of bi-ventricular function and volumes in
pediatric PH.252 MRI-derived functional and volumetric
indices predict morbidity and mortality in pediatric PH
and may provide additional information with respect to
inter-ventricular interactions.120,275 In addition, phase-con-
trast MRI remains the state-of-the-art flow imaging tech-
nique enabling precise flow volume quantification and
consequently provides valuable assessment of Qp/Qs ratios
in children with PH associated with congenital heart disease
and intracardiac shunts. Furthermore, parallel or sequential
phase-contrast MRI and pressure evaluation in the catheter-
ization lab has been proposed as a novel and potentially
more reliable method for the calculation of PVR in com-
parison to standard Fick principle or thermodilution.276,277
Recent studies suggest that pulsatile pulmonary vascular
stiffness indices derived by phase-contrast MRI and ultra-
sound may have a strong prognostic potential to predict
both hard and soft outcomes in pediatric PH.278–280
Lastly, MRA can aid with differential diagnosis by fine
characterization of the pulmonary vasculature and exclusion
of thrombi. Unlike echocardiography, cardiac MRI is
currently not suitable for frequent serial assessment due to
its clinical availability, longer post-processing time, and also
due to the necessary anesthesia required for younger chil-
dren and neonates.
In summary, children pose a different set of challenges to
adult populations when it comes to imaging. Given the
proven benefits of imaging adults with PH, it is appropriate
that all patients including children are allowed to experience
these benefits. Appropriate adaptations to imaging strategy
and environment can achieve high-quality results in the vast
majority of pediatric patients.
Section 5 Future directions
5.1 Applications of computational modelling and artificial
intelligence (AI) in pulmonary hypertension
Summary statements
1. Physiological modeling can be used to characterize the
behavior of the cardiopulmonary system.
2. Computational models assessing PA flow have high diag-
nostic accuracy in suspected PH.
3. Machine learning approaches may assist image segmen-
tation and improve diagnostic and prognostic
assessments.
4. Further work to assess computational approaches versus
current diagnostic approaches in PH is recommended.
Imaging modalities and markers derived based on images
alone have been shown to have clinical potential. Their
interpretation could be enriched by introducing additional
knowledge from the application of mathematical models,
which can bring insights into the hemodynamic system
behavior in health and disease.
Based on mathematical and physical principles, models
of the pulmonary circulation are currently being evaluated
in the translational/clinical research. Electrical analogue
(Windkessel or 0D-zero-dimensional) models supplied by
patient-specific 2D phase-contrast MRI data have been pro-
posed281,282 to characterize globally the pulmonary circula-
tion in terms of vascular resistance and compliance in
Table 2. Imaging modalities used in pediatric pulmonary hypertension.
Modality Adaptation Problem
Echocardiography Higher frequency probes provide better spatial and tem-
poral resolution in children; optimized sector width and
focal length improves image quality in children
High heart rate, small structures but better echo windows
reduced distance from probe to structure of interest
CT imaging Multislice Small structures, high heart rates, movement, difficulty in
breath holding, need to avoid sedation anesthesia
MRI Rectangular field of view, partial Fourier encoding, patient-
friendly MRI environment, use of novel real-time
sequences/under-sampling with novel reconstruction
Small structures, high heart rates and respiratory rates,
movement and difficulty breath-holding, need to avoid
anesthesia
CT, computed tomography; MRI, magnetic resonance imaging.
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Table 3. Echocardiographic variables used at diagnosis and follow-up in pediatric PH.
Echo variables Interpretation Advantage Limitations References
Interventricular
septal flattening
Mild, moderate, or severe to indicate the
severity of PH
Quick visual assessments when there is not
adequate TR peak velocity to estimate
RVSP
Qualitative. Can occur in systole and dia-
stole depending on pressure or volume
overload
317,318




RVSP¼ SPAP¼ 4(TR max)2þmRAP. If TR
velocity is >3m/s, PH may be suspected
Easy to obtain 75% is measurable 319
Modest correlation with SPAP
mPAP (mmHg) mPAP¼ 4 V(early peak pulmonary
regurgitation velocity)2þRAP
Alignment of PR maybe better than TR PR required for measurement 260,263
Modest correlation with mPAP





Alignment of PR maybe better than TR PR required for measurement 260,263
TAPSE (mm) Longitudinal systolic function Easy to obtain, impaired RV systolic func-
tion when the TAPSE is <2 standard
deviation of age-related value
Single dimension, does not take into
account of the circumferential or radial
function of the RV. Alignment can be a
problem
320,321
Poor correlation with RV function and
survival
PAAT (ms) Abnormal PAAT values with z-score <-2
SD were predictive of PH
Can easily be measured in all patients HR-dependent 256,322
RV TDI E’ (cm/s) <8 cm/s may indicate increased risk of
mortality
Can easily be measured in all patients HR-dependent 323
RV TDI MPI Abnormal TDI MPI values indicates right
ventricular dysfunction
Can easily be measured in patients HR-dependent 324
S/D ratio >1.4 indicates severity of PH and
increased risk of mortality





>1 may indicate increased risk of adverse
events in pediatric PH
Easy to obtain clinically Cannot be used in patients with left to
right shunts
325
RV FAC (%) Decreased FAC (<35%) correlates with
decreased systolic function
Clinically easy to obtain Does not take into account of the entire
right ventricle
324
3D RV EF (%) Decreased RV EF (<45%) indicates
decreased RV function
Full volume datasets to evaluate for RV
volumes and function; accurate meas-
urements of RV function and can be
prognostic in PH
Required breath-holding for adequate vol-
umes; can be difficult even in single beat
acquisitions when the pediatric probe is
too big
268,326
RV strain (%) RV free wall longitudinal strain decrease
indicates decreased systolic RV function
RV free wall longitudinal strain maybe
more sensitive in detecting ventricular
function and is prognostic in PH
May not have adequate frame rate when
the heart rate is too high
273
LV EF (%) LV EF may be decreased in severe PH via
RV-LV interaction
Quantification of LV function Bi-plane Simpson’s may not be accurate as
the LV is distorted in severe PH
324
TR, tricuspid regurgitant; RVSP, right ventricle systolic pressure; SPAP, systolic pulmonary arterial pressure; V, velocity; RA, right atrium; PH, pulmonary hypertension; mRAP, mean right atrial pressure; mPAP,
mean pulmonary arterial pressure; RAP, right atrial pressure; DPAP, diastolic pulmonary arterial pressure; PAAT, pulmonary arterial acceleration time; SD, standard deviation; TDI, tissue Doppler imaging; MPI,






























healthy and PH patients. They have also shown promising
results for quantifying the changes of the electric parameters
in patients with PAH, at baseline and follow-up.283 Wave
transmission (one-dimensional [1D]) models are particularly
powerful, as ‘‘waves carry information,’’ and the
energy282,284,285 contained in the backward reflected wave
can be used as an indicator between the right ventricle and
its afterload mismatch. Using a 1D model of a straight elas-
tic tube and temporal MRI flow and area waveforms, it has
been shown that, on average, >40% of the total wave power
was contained in the backward wave measured in patients
with PH, whereas <20% was characteristic to the healthy
volunteers group.282 Different PH heterogeneities can be
mimicked by modifying the structural and elastic param-
eters of a 1D pulmonary tree structure. Several
authors285–287 investigated the pressure and flow waveforms
in healthy and several simulated PH conditions using
numerical solutions of 1D models of the major vessel net-
work. Notably, Qureshi et al.285 changed the configuration
of the structured tree and altering, in turn, the compliance of
the large and small vessels to predict the hemodynamic
changes induced by PAH, CTEPH, and hypoxic lung dis-
ease. The authors showed an increase in the reflected waves
under these simulated conditions, with the potential to dif-
ferentiate between different PH phenotypes.
The 0D and 1D models have the main advantage that they
are relatively simple to implement and do not require signifi-
cant computing resources. However, 3D computational fluid
dynamics (CFD) models are more complex, being able to
provide patient-specific characterization of
hemodynamics.288,289 Full 3D CFD simulations can resolve
the physiological flow field in all three directions and time.
Further post-processing of the CFD results can provide com-
puted metrics (e.g. wall shear stress [WSS]), which give add-
itional insights on disease progression. It has been argued290
that pathological flows in the PA alter cell behavior favoring
vasoconstriction. 3D CFD291,292 studies of the pulmonary
circulation showed that shear stress has an impact on
endothelial health and dysfunction, and reduced WSS in
the proximal PAs were shown to be characteristic to PH
patients.
Machine learning of RV contours to derive tissue motion
has shown to be of prognostic value in PAH and of greater
significance than standard cardiac volumetric metrics.293
Such approaches are of great potential, minimizing user
input/error and potentially providing a more complete prog-
nostic assessment. The added value versus measurements
adjusted for age, sex, and BSA,118,294 or standard CMR
strain parameters in PAH is an area for further work.
Machine learning approaches may significantly improve
the automation and quantification of parameters from ima-
ging. For example, deep learning approaches have already
been utilized for automation of arteriovenous segmentation
of the pulmonary circulation.295
The success of the computational models is closely
related to the available data from the imaging modalities.
Regardless of using the data only to supply the models’
boundary conditions, or integrate it within artificial intelli-
gence algorithms,296,297 the computational models and ima-
ging modalities play together an essential role in the process
Table 4. Echocardiographic views to obtain functional parameters in pediatric PH.
View Functional parameters
Anatomy Parasternal short axis End-systolic RV/LV ratio325
Doppler Parasternal short axis Pulmonary acceleration time/ejection time
Pulmonary regurgitation early and late diastolic velocity
Apical four-chamber Tricuspid regurgitation severity (none, mild, moderate, severe)
Tricuspid regurgitation peak velocity
Myocardial performance index (tricuspid tissue Doppler)327
Systolic/diastolic (S/D) duration ratio from TR Doppler272
Tissue Doppler systolic and diastolic velocities (tricuspid, septal, mitral)
Right atrium Apical four-chamber Right atrial area (RA)
Right ventricle Apical four-chamber Qualitative RV function (good, mildly/moderately/severely depressed)
RV end-diastolic and end-systolic dimensions indexed for BSA (2D)
Fractional area of change (FAC) %
Tricuspid annular planar systolic excursion (TAPSE) with z-score
(M-mode when available, 2D)
RV strain (global and segmental)43,326,328
3D RV volumes and function268,326
Left ventricle Apical two- and four-chamber LV ejection fraction (bi-plane Simpson or 5/6 area-length method)
LV eccentricity index317
LV strain (global)329
3D LV volumes and function324
Other Presence and severity of pericardial effusion (none, small, moderate, large)231
RV, right ventricle; LV, left ventricle; TR, tricuspid regurgitant jet; BSA, body surface area.
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of non-invasive PH diagnostic, prognostic, and understand-
ing of the disease mechanisms.
Section 6 Conclusion and areas of research
priority
In this statement, we have discussed recent advances in ima-
ging techniques in PH and their clinical application. This is
summarized in the PVRI Imaging Task Force diagnostic
algorithm. Rapidly evolving technologies also provide
opportunities to improve our understanding of PH and
assess the impact of much-needed new therapies. This sec-
tion identifies areas requiring further research in addition to
highlighting a number of ongoing and planned studies.
6.1 Establishment of normative ranges and repeatability
of imaging techniques
Despite the widespread use of imaging techniques in clinical
practice, there are only limited data on the impact of age,
sex, and ethnicity on commonly used metrics. The studies
conducted to develop normative equations to allow for cor-
rection have been performed.298–304 However, given the sig-
nificant impact of age, sex, and ethnicity on morphological
characteristics, more research in this area is warranted to
understand variation across populations.
There is increasing interest in using imaging endpoints in
clinical trials to assess treatment response in the clinic setting.
However, there are limited data on the repeatability of car-
diac MRI measurements. The RESPIRE study (clinical-
trials.gov), which should report in the third quarter of
2019, will provide information on the sensitivity to change
relative to measurement repeatability of cardiac MRI mor-
phological and functional data. This will aid the design of
studies considering MRI as a primary endpoint. Even in
the absence of such data, studies such as REPAIR (clinical-
trials.gov) are now using imaging to assess the impact of
pharmacological interventions. The results of these studies
are awaited with interest.
6.2 Comparison of imaging modalities and approaches
There are pros and cons of different imaging modalities with
respect to diagnostic performance, repeatability, availabil-
ity, exposure to ionizing radiation, acceptance to patients,
and cost. Often new imaging modalities and/or approaches
are introduced into clinical practice with limited data. The
cost of conducting large comparative studies and the rapid
advances in the underlying technology that may occur
during the conduct of a study may impact negatively on
decisions to conduct such comparative studies. However,
there is a pressing need to perform such technology apprai-
sals. An important area is the diagnosis of CTEPH, where
there have been significant advances in the imaging of the
pulmonary vasculature. Additional data are required to crit-
ically evaluate these new techniques and challenge current
guideline approaches. Importantly, a number of studies are
planned, including the prospective, multicenter, compara-
tive phase III diagnostic trial CHANGE-MRI, a
European multicenter study comparing functional MRI
and VQ-SPECT. This study aims to recruit 1000 patients
(clinicaltrials.org). The INSPIRE study is a pilot non-
inferiority study comparing iodine subtraction mapping
with VQ-SPECT in patients with suspected CTEPH
(clinicaltrials.gov). A prospective study comparing the
cost and utility of follow-up approaches using echocardiog-
raphy and cardiac MRI in patients with PAH is highly
desirable.
An additional important area of research is the optimiza-
tion of initial diagnostic testing and follow-up based on
imaging availability, particularly where imaging and inva-
sive testing are limited
6.3 Combining imaging with other modalities (genetics
and MRI-augmented right heart catheterization)
With advances in genetics and imaging, there is an opportun-
ity to better understand genotype–phenotype associations that
have the potential to aid clinical decision-making.
Heterozygous mutations in the gene-encoding bone morpho-
gentic protein receptor type 2 (BMPR2) are the most common
genetic cause of PAH, occurring in 15% of cases,185 and
have been associated with worse RV function on cardiac
MRI.305 Bi-allelic mutations in the eukaryotic translation ini-
tiation factor 2 alpha 5 kinase 4 gene (EIF2AK4) are
described in PVOD and PCH,306,307 which are important to
diagnose given their worse prognosis and poorer response to
PAH therapies. In a large international cohort study,185
patients with PVOD were diagnosed based on radiological
criteria; however, a number of patients who were carriers of
EIF2AK4 were not identified by imaging alone. These
patients were younger and had a lower gas transfer factor
and greater interlobular septal thickening and mediastinal
lymphadenopathy. This suggests that combining imaging
with genetic testing in at-risk patients has the potential to
improve diagnostics and prognostication. Integration of gen-
etics, clinical data, and imaging is an exciting area for further
research.
Diagnosis and accurate prognostication in patients with
pulmonary vascular disease remains challenging.
Hemodynamic data from RHC provides important infor-
mation with direct pressure measurement. However, it
does not provide a complete morphological or functional
assessment of the right ventricle and pulmonary circulation.
MRI-augmented catheterization involves invasive RHC per-
formed inside the MRI system.276,308,309 It combines simul-
taneous invasive hemodynamic and MRI morphological
and functional assessment in a single radiation-free proced-
ure, providing detailed physiological insights. Further work
to investigate the potential advantages in terms of clinical
utility, improved understanding of disease, patient accept-
ability, and cost is recommended.
Pulmonary Circulation Volume 9 Number 3 | 19
6.4 Improving our understanding of pulmonary vascular
disease by assessing the distal vasculature and using
novel imaging approaches
A limitation of current imaging modalities in PH is the
insensitivity to visualize and interrogate the distal pulmon-
ary arterial vasculature, the primary site of disease in
patients with PAH. Assessing pulmonary perfusion directly
using novel MRI or CT methods may provide a significant
insight to the underlying small vessel vasculopathy.
Temporal and spatial heterogeneity of the blood flow in
patients at baseline and during PAH therapy is an area for
further research.
Inhaled Xe129 hyperpolarized gas imaging is an emerging
technique. Reports of hyperpolarized gases in CTEPH have
suggested a potential role in follow-up of patients310 and
abnormalities in IPAH have also been reported.311 A patient
inhales Xe129 gas and ventilation images are acquired. Xe129
possesses relatively high solubility in tissues and blood. The
transit of the gas from gas to dissolved phase can be probed
using MRI spectroscopy. This allows the acquisition of
functional parameters characterizing the gas exchange as
well as gas uptake by imaging the dissolved phase. By study-
ing these Xe129 diffusion properties, various microstructure
parameters including alveolar-volume ratio, blood–gas bar-
rier thickness, and surface-to-volume ratio can be
determined.
6.5 Stress imaging of the cardiopulmonary system
Imaging in patients with suspected PH is usually undertaken
at rest but there is increasing interest in evaluating changes
in PAP and RV function on exercise and following other
acute interventions. Exercise echocardiography is well
described312–315 in the assessment of patients with PH, but
currently its use is not widespread. There is increasing inter-
est in using CMR and augmented MRI RHC to assess car-
diopulmonary system on exercise to determine the
differential response of RV morphology and function in
health and disease. Further evaluation of the effect of
acute interventions such as fluid and acute vasodilator chal-
lenges would also be of value.
6.6 Artificial intelligence and applications in
pulmonary hypertension
With the rapid development in machine learning technolo-
gies, there is huge potential to improve imaging assessments.
Image acquisition, analysis, and interpretation are areas that
may benefit from integration of AI technologies. There are a
number of recent publications in this area.293,296,297 Notable
areas for further research include acceleration of MRI
acquisition, improved segmentation of the cardiac cham-
bers on CT and MRI and the pulmonary vasculature on
CT, and diagnostic and prognostic classification and
interpretation.
6.7 The impact of imaging on patients and users
Much of the focus of imaging research is based on the know-
ledge that can obtained by the images themselves. However,
an important area of investigation is the impact of imaging:
on patients and their families, physicians and healthcare
professionals, researchers who interpret the images, and
healthcare systems that fund imaging. The acceptability,
emotional impact, and cost of clinical pathways to diagnose
and serially assess patients requires further research, includ-
ing the relative tolerability, risks, and benefits of different
imaging approaches. A study evaluated the social and
technological epistemology of clinical decision-making as
mediated by imaging.316 This study illustrated that images
can fulfil a mediating role by aiding acquisition of know-
ledge and facilitating communication in addition to illustrat-
ing the highly social aspects of interactions with patients and
within multidisciplinary meetings. Involvement of patients
and their families and users of imaging is required if imaging
is going to fulfil its potential.
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